COVID-19 pill developers aim to top Merck, Pfizer effortsAntivirals, Business, Clinical Data, Clinical Trials, COVID-19 therapeutic candidates, Drug Development, HCV nucleotide analogue NS5B polymerase inhibitors, Merck, Novartis, Pfizer, Pills, R&D, Rivalries, Roche, ShionogiAs Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Read more September 28, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/09/COVID-19-pill-developers-aim-to-top-Merck-Pfizer-efforts-Reuters-9-28-21.jpeg 187 270 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-09-28 14:42:042021-09-28 23:21:21COVID-19 pill developers aim to top Merck, Pfizer efforts